Caixa Capital has recently subscribed to Forbion’s third fund, with a first closing of € 92 million.
Forbion Capital Partners is a dedicated Life Sciences venture capital firm with offices in Naarden (Netherlands), Munich (Germany), and Boston (US). Forbion invests in life sciences companies in drug discovery & development as well as medical device companies addressing substantial unmet medical needs. The new fund will continue Forbion’s proven and successful strategy of investing in world-class companies developing innovative therapeutics, medical devices and (companion) diagnostics.
The team at Forbion has consistently shown its ability to select, start and build winning companies in the EU and beyond, with groundbreaking therapies and technologies that truly represent the future of medicine.
Of the 56 companies the Forbion team has invested in since 1999, 30 have been exited by either trade sale or listing, yelding an IRR of over 30%, one of the strongest financial track records in the industry. Moreover, six of its companies have become so-called “unicorns” in that their valuations have reached USD 1bn or more.
Besides the investment in a player with strong track record, this operation aims to strengthen Forbion’s activity in Portugal, allowing Portuguese startups to access the European venture capital ecosystem.
With the establishment of this international partnership, Caixa Capital reinforces its role as an investor in the internationalization of Portuguese startups.